FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795708883> ?p ?o ?g. }

• W2795708883 abstract "Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) are a favorable predictive factor for EGFR tyrosine kinase inhibitors (TKIs) treatment. For lung cancer patients with EGFR-exon 19 deletions or an exon 21 Leu858Arg mutation, the standard first-line treatment is first-generation (gefitinib, erlotinib), or second-generation (afatinib) TKIs. EGFR TKIs improve response rates, time to progression, and overall survival. Unfortunately, patients with EGFR mutant lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been reported. Optimal treatment for the various mechanisms of acquired resistance is not yet clearly defined, except for the T790M mutation. Repeated tissue biopsy is important to explore resistance mechanisms, but it has limitations and risks. Liquid biopsy is a valid alternative to tissue re-biopsy. Osimertinib has been approved for patients with T790M-positive NSCLC with acquired resistance to EGFR TKI. For other TKI-resistant mechanisms, combination therapy may be considered. In addition, the use of immunotherapy in lung cancer treatment has evolved rapidly. Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment." @default.
• W2795708883 created "2018-04-13" @default.
• W2795708883 creator A5002458975 @default.
• W2795708883 creator A5036843957 @default.
• W2795708883 date "2018-02-19" @default.
• W2795708883 modified "2023-10-14" @default.
• W2795708883 title "Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer" @default.
• W2795708883 cites W1584059175 @default.
• W2795708883 cites W1845440762 @default.
• W2795708883 cites W1908940658 @default.
• W2795708883 cites W1925221217 @default.
• W2795708883 cites W1964081206 @default.
• W2795708883 cites W1971142107 @default.
• W2795708883 cites W1978285367 @default.
• W2795708883 cites W1979536922 @default.
• W2795708883 cites W1980497534 @default.
• W2795708883 cites W1983774108 @default.
• W2795708883 cites W1987283660 @default.
• W2795708883 cites W1988939419 @default.
• W2795708883 cites W1994539763 @default.
• W2795708883 cites W1998971866 @default.
• W2795708883 cites W2003984225 @default.
• W2795708883 cites W2005665711 @default.
• W2795708883 cites W2010507734 @default.
• W2795708883 cites W2013768132 @default.
• W2795708883 cites W2018628280 @default.
• W2795708883 cites W2019607817 @default.
• W2795708883 cites W2030227571 @default.
• W2795708883 cites W2035567127 @default.
• W2795708883 cites W2037139573 @default.
• W2795708883 cites W2039469453 @default.
• W2795708883 cites W2040604770 @default.
• W2795708883 cites W2043696829 @default.
• W2795708883 cites W2046847797 @default.
• W2795708883 cites W2054133698 @default.
• W2795708883 cites W2061932411 @default.
• W2795708883 cites W2063193057 @default.
• W2795708883 cites W2063391304 @default.
• W2795708883 cites W2065477010 @default.
• W2795708883 cites W2065947397 @default.
• W2795708883 cites W2071042296 @default.
• W2795708883 cites W2076178766 @default.
• W2795708883 cites W2083605381 @default.
• W2795708883 cites W2088540000 @default.
• W2795708883 cites W2093613683 @default.
• W2795708883 cites W2095811566 @default.
• W2795708883 cites W2096198395 @default.
• W2795708883 cites W2096786080 @default.
• W2795708883 cites W2099725888 @default.
• W2795708883 cites W2104347254 @default.
• W2795708883 cites W2107503225 @default.
• W2795708883 cites W2112602910 @default.
• W2795708883 cites W2114095518 @default.
• W2795708883 cites W2119152504 @default.
• W2795708883 cites W2120869188 @default.
• W2795708883 cites W2121110176 @default.
• W2795708883 cites W2123648923 @default.
• W2795708883 cites W2123918574 @default.
• W2795708883 cites W2126177831 @default.
• W2795708883 cites W2128208856 @default.
• W2795708883 cites W2129656399 @default.
• W2795708883 cites W2133963438 @default.
• W2795708883 cites W2138200001 @default.
• W2795708883 cites W2138297714 @default.
• W2795708883 cites W2143913849 @default.
• W2795708883 cites W2145980885 @default.
• W2795708883 cites W2146418087 @default.
• W2795708883 cites W2146625800 @default.
• W2795708883 cites W2150371178 @default.
• W2795708883 cites W2150575159 @default.
• W2795708883 cites W2153011818 @default.
• W2795708883 cites W2153733592 @default.
• W2795708883 cites W2154149901 @default.
• W2795708883 cites W2157645333 @default.
• W2795708883 cites W2159013299 @default.
• W2795708883 cites W2160040938 @default.
• W2795708883 cites W2160300997 @default.
• W2795708883 cites W2161821474 @default.
• W2795708883 cites W2163351155 @default.
• W2795708883 cites W2164421236 @default.
• W2795708883 cites W2166084034 @default.
• W2795708883 cites W2167191456 @default.
• W2795708883 cites W2169816570 @default.
• W2795708883 cites W2170481827 @default.
• W2795708883 cites W2171139285 @default.
• W2795708883 cites W2198093519 @default.
• W2795708883 cites W2207941545 @default.
• W2795708883 cites W2218718059 @default.
• W2795708883 cites W2235523093 @default.
• W2795708883 cites W2256191967 @default.
• W2795708883 cites W2280175247 @default.
• W2795708883 cites W2292347930 @default.
• W2795708883 cites W2297863576 @default.
• W2795708883 cites W2328294134 @default.
• W2795708883 cites W2336745060 @default.
• W2795708883 cites W2337507927 @default.
• W2795708883 cites W2340070077 @default.
• W2795708883 cites W2340752593 @default.
• W2795708883 cites W2343785408 @default.
• W2795708883 cites W2386279287 @default.

• next